olfactory receptor family 10 subfamily AH member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR10AH1P profile across patient tissues and cancer cell-line models. OR10AH1P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, OR10AH1P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, OR10AH1P RNA expression shows 6,858 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where OR10AH1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10AH1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10AH1P survival associations across molecular data types. OR10AH1P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10AH1P RNA expression–survival associations across cancer types. High OR10AH1P expression shows unfavorable associations in MESO and LIHC, but favorable associations in HNSC, LAML, LUSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for OR10AH1P RNA expression.
This table summarizes OR10AH1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR10AH1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10AH1P shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, KICH and LUAD. The HNSC box plot shows higher OR10AH1P RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p = .010).
This table shows molecular features associated with OR10AH1P in patient tissues and cancer cell lines. In patient samples, OR10AH1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
